Report from Annual General Meeting of Vitrolife AB (publ)

At Vitrolife’s Annual General Meeting yesterday, May 5, the following, amongst
other things, was decided:

  · The Board’s proposed dividend of SEK 1.00 per share for the financial year
2013 was approved. Thursday May 8, 2014 was adopted as the record day.

  · Re-election of Board members Fredrik Mattsson, Tord Lendau, Maris Hartmanis,
Barbro Fridén, Carsten Browall and Pia Marions, in accordance with the election
committee’s proposal. Carsten Browall was re-elected Chairman of the Board.

  · Remuneration to the members of the Board shall be totalling SEK 1,110,000,
of which SEK 330,000 is allocated to the Chairman of the Board, SEK 150,000 to
each of the other Board members and SEK 30,000 to the chairman in the Audit
Committee.

  · Election of Deloitte AB, with authorized public accountant Jan Nilsson as
head auditor, and authorized public accountant Fredrik Jonsson as auditors for a
term of 3 years.

  · Authorization for the Board, for the time up until the next Annual General
Meeting and on one or more occasions, to take a decision on the issue of a
maximum of 1,980,000 shares in total, corresponding to just below 10 percent of
the company’s share capital.

  · The Board was authorized to take a decision, up until the next Annual
General Meeting and on one or more occasions, with regard to the acquisition of
the company’s own shares. The Company can at no time hold more than 10 percent
of the total shares in the Company.

  · The proposed principles for remuneration and other conditions of employment
for the senior management were approved.

May 6, 2014

Gothenburg, Sweden
VITROLIFE AB (publ)
The Board
Contact:
Carsten Browall, Chairman of the Board, phone 46 70-255 65 32
Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on May 6,
2014 at 8.30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical
device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/)
product area develops, produces and markets medical devices for assisted
reproduction. Work is also carried out to enable the use and handling of stem
cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 240
employees and the company's products are sold in almost 110 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/